- Home
- IRS vs GHRS Comparison
IRS vs GHRS Comparison
Compare IRS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRS
- GHRS
- Stock Information
- Founded
- IRS 1943
- GHRS 2018
- Country
- IRS Argentina
- GHRS Ireland
- Employees
- IRS N/A
- GHRS N/A
- Industry
- IRS Homebuilding
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- IRS Real Estate
- GHRS Health Care
- Exchange
- IRS Nasdaq
- GHRS Nasdaq
- Market Cap
- IRS 1.1B
- GHRS 868.7M
- IPO Year
- IRS 1994
- GHRS 2021
- Fundamental
- Price
- IRS $14.15
- GHRS $12.51
- Analyst Decision
- IRS Strong Buy
- GHRS Strong Buy
- Analyst Count
- IRS 1
- GHRS 3
- Target Price
- IRS $12.62
- GHRS $35.67
- AVG Volume (30 Days)
- IRS 160.9K
- GHRS 1.1M
- Earning Date
- IRS 02-07-2025
- GHRS 03-07-2025
- Dividend Yield
- IRS 11.53%
- GHRS N/A
- EPS Growth
- IRS N/A
- GHRS N/A
- EPS
- IRS N/A
- GHRS N/A
- Revenue
- IRS $325,094,048.00
- GHRS N/A
- Revenue This Year
- IRS N/A
- GHRS N/A
- Revenue Next Year
- IRS N/A
- GHRS N/A
- P/E Ratio
- IRS N/A
- GHRS N/A
- Revenue Growth
- IRS N/A
- GHRS N/A
- 52 Week Low
- IRS $7.32
- GHRS $6.00
- 52 Week High
- IRS $17.67
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- IRS 46.29
- GHRS 51.44
- Support Level
- IRS $13.85
- GHRS $13.50
- Resistance Level
- IRS $14.40
- GHRS $14.91
- Average True Range (ATR)
- IRS 0.72
- GHRS 1.58
- MACD
- IRS 0.08
- GHRS -0.22
- Stochastic Oscillator
- IRS 69.07
- GHRS 5.56
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.